Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. The company plans to increase enrollment from 12 to 36 patients, citing continued safety, tolerability and early clinical activity. It aims to further assess dose optimization and preliminary efficacy with pembrolizumab and chemotherapy, and expects updates through 2026–2027.
How this was made
The 30-second read
Why it matters
Expanding Phase 1b enrollment should yield a larger and more statistically meaningful early dataset for ORR, PFS, and translational biomarkers, potentially strengthening the case for later-stage development or partnership discussions.
Market read
A straightforward clinical trial expansion is a tradable biotech catalyst, with expectations centered on improved early efficacy/biomarker visibility over 2026–2027.
What to watch
The company withdrew ASCO 2026 abstracts for IP reasons—market may initially misread this as negative sentiment despite management stating it was unrelated to safety/clinical concerns.
Background
Kazia’s paxalisib is an investigational brain-penetrant PI3K/Akt/mTOR pathway inhibitor being tested in multiple oncology settings; this update targets advanced triple-negative breast cancer with immunotherapy/chemo combinations.
Ticker impact
Kazia plans to expand its Phase 1b paxalisib trial in advanced TNBC, increasing enrollment from 12 to 36 based on encouraging safety/tolerability.
Near-term upside bias as investors price in more informative ORR/PFS and translational data; magnitude likely limited by Phase 1b early-stage nature.
The news is a concrete clinical development step with a clear enrollment increase and stated intent to better assess ORR/PFS/biomarkers, but it remains early-stage and open-label, reducing certainty on ultimate value creation.
Market effects
Supports sentiment for PI3K/mTOR pathway inhibitors and combination immuno-oncology approaches in TNBC, though impact is company-specific.
Primarily impacts US-listed small-cap biotech sentiment; limited direct regional spillover beyond clinical-readthrough trading.
TNBC remains a global unmet-need area; however, the preclinical support and Phase 1b nature constrain broad global read-across.
Counterpoint
Enrollment expansion does not guarantee improved efficacy; Phase 1b open-label results may still fail to translate into meaningful ORR/PFS.
Key entities
- companyKazia Therapeutics
Expanding its ongoing Phase 1b paxalisib trial in advanced TNBC from 12 to 36 patients based on encouraging safety/tolerability.
- drugpaxalisib
PI3K/Akt/mTOR inhibitor being evaluated in combination with pembrolizumab and chemotherapy.
- drugpembrolizumab
Checkpoint inhibitor used in combination with paxalisib and chemotherapy in the trial.
